GSK Wins World's First Approval for Hepatitis B Functional Cure in Japan

GSK (LSE:GSK) has received the world's first regulatory approval for Hibsago (bepirovirsen) as a functional cure for chronic hepatitis B virus infection in Japan. The clearance follows Phase III trial data that showed significant functional cure rates in patients with chronic hepatitis B.

The decision represents an important development for GSK's pipeline and may influence the standard of care for chronic hepatitis B treatment globally. A functional cure option for hepatitis B broadens GSK's infectious-disease portfolio beyond prevention and treatment of acute illness.

GSK is a large pharmaceuticals company with a reported market cap of about £75.0 billion that focuses on vaccines and specialty medicines across major markets including the United Kingdom and the United States. The company still needs to show how bepirovirsen access, pricing and follow-on indications compare against peers such as Pfizer and Merck in antiviral markets.